In this article, we will look at the Top 12 Blue Chip Stocks to Buy At 52-Week Lows.
On September 30, Elyse Ausenbaugh, Head of Investment Strategy at JPMorgan Wealth Management, joined CNBC for an interview to discuss the current market rally. She noted that there is a strong momentum going forward in 2025, which is likely to continue in 2026 as well. She sees improvements in the macroeconomic environment and anticipates powerful tailwinds from significant investments in AI.
She highlighted that the current rally is driven by various factors, including the Federal Reserve cutting cycle, corporate profit margins, and infrastructural investments fueling earnings growth. In addition to this, the easing of the tariff uncertainty also acts as a positive factor for the market.
While talking about the labor market, Ausenbaugh noted that the market is bending, not breaking. She highlighted that the hiring has been slow; however, layoffs are not expected to rise anymore. While elaborating, she noted that this is because the corporate profits have been strong and companies are unlikely to lay off unless the profit weakens greatly. Ausenbaugh believes that the upside potential suggests it is a good time to stay invested in the market.
With that, let’s take a look at the Top 12 Blue Chip Stocks to Buy At 52-Week Lows.
Our Methodology
To curate the list of Top 12 Blue Chip Stocks to Buy At 52-Week Lows, we sifted through reputable financial media to get a list of Blue Chip stocks trading between 0% to 10% of their 52-week lows. Next, we cross-checked the stock price and 52-week lows from Yahoo Finance and ranked the stocks in ascending order of the number of hedge fund holders sourced from Insider Monkey’s Q2 2025 database. Please note that the data was recorded on September 29, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Top 12 Blue Chip Stocks to Buy At 52-Week Lows
12. Unilever PLC (NYSE:UL)
Price: $59.17
52-Week Range: $54.32 – $65.66
Number of Hedge Fund Holders: 27
Unilever PLC (NYSE:UL) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 30, David Hayes from Jefferies maintained a Sell rating on Unilever PLC (NYSE:UL) and reduced the price target from 3,900p to 3,800.00p.
The analyst noted that his main concern is the company’s struggles in emerging markets, such as Latin America. The tough market conditions and pricing pressures in these markets are limiting growth. He highlighted that as a result, the expected growth in this region is much lower than what the analysts forecast.
Moreover, Unilever PLC (NYSE:UL) is also facing difficulty in other key markets, including India and China. He noted that these issues weigh down the company’s overall growth prospects. On the positive side, the company is performing moderately well in developed markets, with growth slightly better than expected.
Unilever PLC (NYSE:UL) is a UK-based fast-moving consumer goods company that sells products in five main areas, including Beauty & Wellbeing, Personal Care, Home Care, Foods, and Ice Cream.
11. Amgen Inc. (NASDAQ:AMGN)
Price: $273.97
52-Week Range: $253.30 – $335.88
Number of Hedge Fund Holders: 62
Amgen Inc. (NASDAQ:AMGN) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 26, Reuters reported that global drugmakers are rushing to increase their manufacturing capacity in the United States as the Trump administration is imposing hefty tariffs on pharmaceutical imports.
As a result, Amgen Inc. (NASDAQ:AMGN) is also ramping up investment to enhance its manufacturing capacity in the United States. The company earlier in August announced a $900 million investment to expand its Ohio manufacturing facility, taking its total investment in the state to $1.4 billion. More recently, in September, Amgen Inc. (NASDAQ:AMGN) announced its plan to invest more than $600 million to build a new research and development center in California. It is also investing another $650 million to expand drug manufacturing in Puerto Rico.
Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers and develops medicines for serious diseases.
